Urea derivatives carrying a thiophenylthiazole moiety: Design, synthesis, and evaluation of antitubercular and InhA inhibitory activities

The recent emergence of drug‐resistant strains of Mycobacterium tuberculosis (Mtb) has complicated and significantly slowed efforts to eradicate and/or reduce the worldwide incidence of life‐threatening acute and chronic cases of tuberculosis. To overcome this setback, researchers have increased the...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2022-09, Vol.83 (6), p.1292-1304
Main Authors: Keleş Atıcı, Rüveyde, Doğan, Şengül Dilem, Gündüz, Miyase Gözde, Krishna, Vagolu Siva, Chebaiki, Melina, Homberset, Håvard, Lherbet, Christian, Mourey, Lionel, Tønjum, Tone
Format: Article
Language:English
Subjects:
Acyl carrier protein
Antimicrobial agents
antimycobacterial
Chemical Sciences
Chemical synthesis
Clinical isolates
Cytotoxicity
drug‐resistant clinical isolates
enoyl acyl carrier protein reductase
Hybridization
Isoniazid
Medicinal Chemistry
Molecular docking
Mutation
Mycobacterium tuberculosis
Reductases
Structural analysis
thiazole
thiophene
Toxicity
Tuberculosis
Urea
Ureas
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent emergence of drug‐resistant strains of Mycobacterium tuberculosis (Mtb) has complicated and significantly slowed efforts to eradicate and/or reduce the worldwide incidence of life‐threatening acute and chronic cases of tuberculosis. To overcome this setback, researchers have increased the intensity of their work to identify new small‐molecule compounds that are expected to remain efficacious antimicrobials against Mtb. Here, we describe our effort to apply the principles of molecular hybridization to synthesize 16 compounds carrying thiophene and thiazole rings beside the core urea functionality (TTU1–TTU16). Following extensive structural characterization, the obtained compounds were initially evaluated for their antimycobacterial activity against Mtb H37Rv. Subsequently, three derivatives standing out with their anti‐Mtb activity profiles and low cytotoxicity (TTU5, TTU6, and TTU12) were tested on isoniazid‐resistant clinical isolates carrying katG and inhA mutations. Additionally, due to their pharmacophore similarities to the well‐known InhA inhibitors, the molecules were screened for their enoyl acyl carrier protein reductase (InhA) inhibitory potentials. Molecular docking studies were performed to support the experimental enzyme inhibition data. Finally, drug‐likeness of the selected compounds was established by theoretical calculations of physicochemical descriptors.
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.21958